Literature DB >> 3407378

Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients.

P Marchetti1, L Benzi, M Cerri, P Cecchetti, R Giannarelli, M Giannecchini, G Di Cianni, R Cristofani, R Miccoli, A Bertolotto.   

Abstract

In this study we evaluated the relationships between plasma metformin levels, measured by reverse-phase high-performance liquid chromatography, and serum lipid levels in 20 metformin-treated, type II diabetic patients. Mean fasting plasma metformin concentration was 490 +/- 188 ng/ml. No correlation was found between daily dose of drug and lipid parameters. A significant correlation emerged between circulating metformin concentration and serum triglycerides (r = -0.574, p less than 0.01), HDL-cholesterol (r = 0.583, p less than 0.01) and HDL2-cholesterol (r = 0.670, p less than 0.05). Multiple linear regression analysis showed that the correlation between plasma metformin concentration and serum triglycerides still remained significant after correction for other clinical and metabolic parameters. Total cholesterol and HDL3-cholesterol were not correlated with metformin concentrations. These results demonstrate the clinical usefulness of measuring plasma metformin concentrations and indicate that some effects of metformin on lipid metabolism depend on the drug plasma levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3407378     DOI: 10.1007/bf02581246

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  18 in total

1.  Localization of apolipoprotein B in intestinal epithelial cells.

Authors:  R M Glickman; J Khorana; A Kilgore
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

2.  Effect of phenformin on lipid transport in hypertriglyceridemia.

Authors:  R W Stout; J D Brunzell; D Porte; E L Bierman
Journal:  Metabolism       Date:  1974-09       Impact factor: 8.694

3.  Butylbiguanide concentration in plasma, liver, and intestine after intravenous and oral administration to man.

Authors:  W Lintz; W Berger; W Aenishaenslin; V Kutova; C Baerlocher; J P Kapp; R Beckmann
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

4.  Metformin administration in hyperlipidemic states.

Authors:  A Gustafson; P Björntorp; M Fahlén
Journal:  Acta Med Scand       Date:  1971-12

5.  Effect of metformin on lipid metabolism in the rabbit aortic wall.

Authors:  G Marquié
Journal:  Atherosclerosis       Date:  1978-07       Impact factor: 5.162

6.  Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure.

Authors:  L I Gidez; G J Miller; M Burstein; S Slagle; H A Eder
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

7.  The endothelium, triglyceride-rich lipoproteins, and atherosclerosis: insights from cell biology and lipid metabolism.

Authors:  C J Fielding
Journal:  Diabetes       Date:  1981       Impact factor: 9.461

Review 8.  Metformin: a review of its pharmacological properties and therapeutic use.

Authors:  L S Hermann
Journal:  Diabete Metab       Date:  1979-09

9.  Plasma biguanide levels are correlated with metabolic effects in diabetic patients.

Authors:  P Marchetti; L Benzi; P Cecchetti; R Giannarelli; C Boni; D Ciociaro; A M Ciccarone; G Di Cianni; A Zappella; R Navalesi
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

10.  Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease.

Authors:  C R Sirtori; G Franceschini; G Gianfranceschi; M Sirtori; G Montanari; E Bosisio; E Mantero; A Bondioli
Journal:  J Cardiovasc Pharmacol       Date:  1984 Sep-Oct       Impact factor: 3.105

View more
  5 in total

Review 1.  Clinical pharmacokinetics of metformin.

Authors:  A J Scheen
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

2.  SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.

Authors:  Peter C Hart; Tatsuyuki Chiyoda; Xiaojing Liu; Melanie Weigert; Marion Curtis; Chun-Yi Chiang; Rachel Loth; Ricardo Lastra; Stephanie M McGregor; Jason W Locasale; Ernst Lengyel; Iris L Romero
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

3.  Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.

Authors:  Juliana Levy; Roberta A Cobas; Marília B Gomes
Journal:  Diabetol Metab Syndr       Date:  2010-03-18       Impact factor: 3.320

Review 4.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

5.  Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment.

Authors:  Helen L Barrett; Kathryn L Gatford; Candice M Houda; Miles J De Blasio; H David McIntyre; Leonie K Callaway; Marloes Dekker Nitert; Suzette Coat; Julie A Owens; William M Hague; Janet A Rowan
Journal:  Diabetes Care       Date:  2012-10-09       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.